Extract from the Register of European Patents

EP About this file: EP1523331

EP1523331 - THERAPEUTIC TB VACCINE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.01.2014
Database last updated on 28.02.2026
Most recent event   Tooltip17.07.2015Lapse of the patent in a contracting state
New state(s): HU, LU
published on 19.08.2015  [2015/34]
Applicant(s)For all designated states
Statens Serum Institut
Artillerivej 5
2300 Copenhagen S / DK
[2013/08]
Former [2011/35]For all designated states
Statens Serum Institut
Orestads Boulevard 5
2300 Copenhagen S / DK
Former [2005/16]For all designated states
Statens Serum Institut
Artillerivej 5
2300 Copenhagen S / DK
Inventor(s)01 / ANDERSEN, Peter
Sparresholmvej 47
DK-2700 Bronshoj / DK
02 / ROSENKRANDS, Ida
Kastaniehaven 9
DK-3500 Vaerlose / DK
03 / STRYHN, Anette
Astilbehaven 160, St. tv.
DK-2830 Virum / DK
 [2005/16]
Representative(s)Plougmann Vingtoft a/s
Strandvejen 70
2900 Hellerup / DK
[N/P]
Former [2013/09]Plougmann & Vingtoft A/S
Rued Langgaards Vej 8
2300 Copenhagen S / DK
Former [2005/16]Plougmann & Vingtoft A/S
Sundkrogsgade 9, P.O. Box 831
2100 Copenhagen O / DK
Application number, filing date03763613.108.07.2003
[2005/16]
WO2003DK00477
Priority number, dateDK2002000109813.07.2002         Original published format: DK 200201098
[2005/16]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2004006952
Date:22.01.2004
Language:EN
[2004/04]
Type: A2 Application without search report 
No.:EP1523331
Date:20.04.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 22.01.2004 takes the place of the publication of the European patent application.
[2005/16]
Type: B1 Patent specification 
No.:EP1523331
Date:27.02.2013
Language:EN
[2013/09]
Search report(s)International search report - published on:EP18.03.2004
ClassificationIPC:A61K39/04, C07K14/35, A61P31/06, C12Q1/04
[2005/16]
CPC:
A61K39/04 (EP,US); C07K14/35 (US); A61P31/06 (EP);
A61K2039/55572 (EP,US)
C-Set:
A61K39/04, A61K2300/00 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/16]
TitleGerman:THERAPEUTISCHES VAKZIN GEGEN TUBERKULOSIS[2005/16]
English:THERAPEUTIC TB VACCINE[2005/16]
French:VACCIN THERAPEUTIQUE CONTRE LA TUBERCULOSE[2005/16]
Entry into regional phase11.02.2005National basic fee paid 
11.02.2005Designation fee(s) paid 
11.02.2005Examination fee paid 
Examination procedure11.02.2005Examination requested  [2005/16]
15.02.2005Amendment by applicant (claims and/or description)
21.07.2010Despatch of a communication from the examining division (Time limit: M04)
23.11.2010Reply to a communication from the examining division
03.12.2010Despatch of a communication from the examining division (Time limit: M04)
11.04.2011Reply to a communication from the examining division
13.09.2011Despatch of a communication from the examining division (Time limit: M04)
19.01.2012Reply to a communication from the examining division
07.09.2012Communication of intention to grant the patent
14.01.2013Fee for grant paid
14.01.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  21.07.2010
Opposition(s)28.11.2013No opposition filed within time limit [2014/06]
Fees paidRenewal fee
23.09.2005Renewal fee patent year 03
24.07.2006Renewal fee patent year 04
20.07.2007Renewal fee patent year 05
18.07.2008Renewal fee patent year 06
24.07.2009Renewal fee patent year 07
23.07.2010Renewal fee patent year 08
20.07.2011Renewal fee patent year 09
19.07.2012Renewal fee patent year 10
Penalty fee
Additional fee for renewal fee
31.07.200503   M06   Fee paid on   23.09.2005
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU08.07.2003
AT27.02.2013
BE27.02.2013
CY27.02.2013
CZ27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
IT27.02.2013
MC27.02.2013
NL27.02.2013
RO27.02.2013
SE27.02.2013
SI27.02.2013
SK27.02.2013
TR27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
PT27.06.2013
GB08.07.2013
IE08.07.2013
LU08.07.2013
CH31.07.2013
FR31.07.2013
LI31.07.2013
[2015/34]
Former [2015/32]AT27.02.2013
BE27.02.2013
CY27.02.2013
CZ27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
IT27.02.2013
MC27.02.2013
NL27.02.2013
RO27.02.2013
SE27.02.2013
SI27.02.2013
SK27.02.2013
TR27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
PT27.06.2013
GB08.07.2013
IE08.07.2013
CH31.07.2013
FR31.07.2013
LI31.07.2013
Former [2014/33]AT27.02.2013
BE27.02.2013
CY27.02.2013
CZ27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
IT27.02.2013
MC27.02.2013
NL27.02.2013
RO27.02.2013
SE27.02.2013
SI27.02.2013
SK27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
PT27.06.2013
GB08.07.2013
IE08.07.2013
CH31.07.2013
FR31.07.2013
LI31.07.2013
Former [2014/24]AT27.02.2013
BE27.02.2013
CY27.02.2013
CZ27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
IT27.02.2013
MC27.02.2013
NL27.02.2013
RO27.02.2013
SE27.02.2013
SI27.02.2013
SK27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
PT27.06.2013
GB08.07.2013
CH31.07.2013
FR31.07.2013
LI31.07.2013
Former [2014/21]AT27.02.2013
BE27.02.2013
CY27.02.2013
CZ27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
IT27.02.2013
MC27.02.2013
NL27.02.2013
RO27.02.2013
SE27.02.2013
SI27.02.2013
SK27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
PT27.06.2013
GB08.07.2013
CH31.07.2013
LI31.07.2013
Former [2014/20]AT27.02.2013
BE27.02.2013
CY27.02.2013
CZ27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
IT27.02.2013
MC27.02.2013
NL27.02.2013
RO27.02.2013
SE27.02.2013
SI27.02.2013
SK27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
PT27.06.2013
CH31.07.2013
LI31.07.2013
Former [2014/14]AT27.02.2013
BE27.02.2013
CY27.02.2013
CZ27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
IT27.02.2013
MC27.02.2013
NL27.02.2013
RO27.02.2013
SE27.02.2013
SI27.02.2013
SK27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
PT27.06.2013
Former [2014/03]AT27.02.2013
BE27.02.2013
CY27.02.2013
CZ27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
IT27.02.2013
NL27.02.2013
RO27.02.2013
SE27.02.2013
SI27.02.2013
SK27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
PT27.06.2013
Former [2013/52]AT27.02.2013
BE27.02.2013
CY27.02.2013
CZ27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
NL27.02.2013
RO27.02.2013
SE27.02.2013
SI27.02.2013
SK27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
PT27.06.2013
Former [2013/49]AT27.02.2013
BE27.02.2013
CZ27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
NL27.02.2013
RO27.02.2013
SE27.02.2013
SI27.02.2013
SK27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
PT27.06.2013
Former [2013/48]AT27.02.2013
BE27.02.2013
DK27.02.2013
EE27.02.2013
FI27.02.2013
NL27.02.2013
SE27.02.2013
SI27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
PT27.06.2013
Former [2013/40]AT27.02.2013
BE27.02.2013
FI27.02.2013
SE27.02.2013
SI27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
PT27.06.2013
Former [2013/38]AT27.02.2013
BE27.02.2013
FI27.02.2013
SE27.02.2013
SI27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
Former [2013/37]AT27.02.2013
FI27.02.2013
SE27.02.2013
SI27.02.2013
BG27.05.2013
GR28.05.2013
ES07.06.2013
Former [2013/36]AT27.02.2013
SE27.02.2013
BG27.05.2013
ES07.06.2013
Former [2013/34]SE27.02.2013
BG27.05.2013
Documents cited:Search[X] WO02054073  (US GOV HEALTH & HUMAN SERV et al.) [X] 1,2,6,20-22 * page 2, line 36 - line 39 * * page 3, line 6 - line 8 * * page 3, line 17 - line 20 * * page 9, line 8 - line 19 * * page 15, line 29 - line 35 * * page 25, line 2 - line 13 * * page 27, line 11 - line 12 * * page 20, line 1 - line 23 * * page 26, line 24 - line 34 *
 [X] WO0248391  (INST OF MOLECUL & CELL BIOLOGY et al.) [X] 1,2,6,20-22 * page 1, line 9 - line 32 * * page 2, line 9 - line 15 * * page 3, line 5 - line 30 * * page 12, line 23 - line 26 *
 [DX] WO0179274  (STATENS SERUMINSTITUT et al.) [DX] 1,2,6,20-22 * page 15 - page 16 * * page 17, line 28 - page 18, line 9 * * page 46, line 8 - line 10 * * page 47, line 6 - line 8 *
 [X] WO9735611  (UNIV JOHNS HOPKINS et al.) [X] 21,22 * page 1, line 4 - line 6 * * page 10, line 4 - line 5 * * page 14, line 7 - line 10 * * page 14, line 29 - page 15, line 7 *
 [A] US6294328  (FLEISCHMANN ROBERT DAVID et al.) [A] 1-22 * the whole document *
 [A] US6291190  (BEHR MARCEL et al.) [A] 1-22 * abstract *
International search[X]   BERND HUTTER ET AL: "Up-regulation of narX, encoding a putative "fused nitrate reductase" in anaerobic dormant Mycobacterium bovis BCG", FEMS MICROBIOLOGY LETTERS, vol. 178, 1999, pages 63 - 69, XP002260863, ISSN: 0378-1097 [X] 21,22 * page 68, column L, paragraph 3 * * page 66; table 1 * * abstract *

DOI:   http://dx.doi.org/10.1016/S0378-1097(99)00348-1
 [X]   DATABASE EMBL [online] SWALL; 1 June 1998 (1998-06-01), XP002260867, Database accession no. O53624 [X] 6-8,11 * abstract *
 [A]   ULRICHS TIMO ET AL: "Mycobacterial persistence and immunity", FRONTIERS IN BIOSCIENCE, vol. 7, no. Cited May17, 2002, 1 February 2002 (2002-02-01), pages d458 - 469, XP002260864, ISSN: 1093-4715 [A] 9,10,12-17 * page 465, column R, paragraph 4 *
 [DA]   SHERMAN DAVID R ET AL: "Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystallin", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 98, no. 13, 19 June 2001 (2001-06-19), June 19, 2001, pages 7534 - 7539, XP002260865, ISSN: 0027-8424 [DA] 1-19,21,22 * page 7536; table 1 * * abstract *

DOI:   http://dx.doi.org/10.1073/pnas.121172498
 [DA]   BETTS J C ET AL: "Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling", MOLECULAR MICROBIOLOGY, BLACKWELL SCIENTIFIC, OXFORD, GB, vol. 43, no. 3, February 2002 (2002-02-01), pages 717 - 731, XP002223692, ISSN: 0950-382X [DA] 1-19,21,22 * page 717 * * page 723; table 3 * * page 727, column R, paragraph 1 *

DOI:   http://dx.doi.org/10.1046/j.1365-2958.2002.02779.x
 [DA]   ROSENKRANDS IDA ET AL: "Hypoxic response of Mycobacterium tuberculosis studied by metabolic labeling and proteome analysis of cellular and extracellular proteins.", JOURNAL OF BACTERIOLOGY. UNITED STATES JUL 2002, vol. 184, no. 13, July 2002 (2002-07-01), pages 3485 - 3491, XP002260866, ISSN: 0021-9193 [DA] 1-19,21,22 * the whole document *

DOI:   http://dx.doi.org/10.1128/JB.184.13.3485-3491.2002
 [DA]   BOON C ET AL: "PROTEINS OF MYCOBACTERIUM BOVIS BCG INDUCED IN THE WAYNE DORMANCY MODEL", JOURNAL OF BACTERIOLOGY, WASHINGTON, DC, US, vol. 183, no. 8, April 2001 (2001-04-01), pages 2672 - 2676, XP001077793, ISSN: 0021-9193 [DA] 1-19,21,22 * abstract *

DOI:   http://dx.doi.org/10.1128/JB.183.8.2672-2676.2001
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.